Market research
ONC.LSE Oncimmune Holdings plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 50
- Dividend yield
- Not available
- Beta
- 1.81
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BYQ94H38
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 50
- Dividend yield
- Not available
- Beta
- 1.81
About
About Oncimmune Holdings plc
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse event (irAE) prediction, patient screening, and diagnostic accuracy; Sero Tag, a discovery engine for the identification of relevant biomarker pool for target discovery or companion diagnostics; NavigAID for creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. It also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ONC.LSE discussion.
5 years, 5 months ago
Oncimmune Holdings plc is currently in a long term downtrend where the price is trading 7.6% below its 200 day moving average.
From a valuation standpoint, the stock is 86.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 59.5.
Oncimmune Holdings plc's total revenue sank by 0.0% to $154K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 38.2% to $-2M since the same quarter in the previous year.
Based on the above factors, Oncimmune Holdings plc gets an overall score of 2/5.